Progenics pharmaceuticals inc (PGNX)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues:
Revenue

6,248

15,126

5,613

9,966

4,281

3,238

5,317

3,878

3,189

3,889

2,697

2,765

2,347

-1,373

53,850

8,476

8,476

5,095

1,396

1,937

248

-571

41,656

1,477

1,815

2,968

867

1,801

2,226

8,885

1,117

1,820

2,226

-

5,804

74,407

-

-

-

Research grants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

77

198

71

243

88

86

464

1,681

1,401

1,264

1,234

789

Other revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8

23

23

80

5

19

9

4

7

38

31

14

3

34

18

28

10

19

15

88

28

19

41

31

55

Operating expenses:
Cost of goods sold

1,558

-

1,317

493

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

10,367

12,312

11,439

13,080

12,392

9,600

8,090

9,347

8,110

10,948

10,344

11,292

10,005

11,766

9,827

7,988

7,988

7,941

7,048

6,718

6,489

7,097

6,728

7,848

6,919

8,371

7,905

9,585

8,721

4,915

7,551

7,957

10,909

8,296

12,406

13,302

19,179

12,967

10,659

Selling, general and administrative

10,509

12,571

11,473

14,570

9,224

8,090

7,075

7,569

6,697

6,923

5,958

6,333

5,695

4,938

7,220

5,599

5,599

3,760

4,572

6,127

3,725

4,333

3,895

3,856

3,405

4,197

3,131

3,899

4,314

3,461

4,007

4,025

3,721

4,035

4,064

4,952

5,197

5,414

5,680

Intangible impairment charge

-

-

-

-

-

-

23,200

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

License fees - research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

160

180

90

-

91

153

70

510

510

110

40

12

114

88

364

110

291

Total revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,388

1,967

2,305

Royalty expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

169

147

82

-

73

119

116

79

73

162

185

131

147

70

57

62

58

Depreciation and amortization

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

142

133

144

-

179

318

277

261

291

300

472

485

520

525

536

532

874

Intangible impairment charges

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

576

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Change in contingent consideration liability

-300

-400

-500

916

900

100

-8,000

1,300

800

-700

700

700

1,900

-6,400

600

600

600

700

-200

800

300

100

500

400

500

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

22,134

25,841

23,729

29,059

22,516

17,790

30,365

18,216

15,607

17,171

17,002

18,325

17,600

10,304

17,647

14,187

14,187

12,401

11,420

13,645

10,514

12,383

12,170

12,564

11,140

11,891

11,379

14,074

13,498

9,226

12,432

12,554

15,327

12,959

17,251

18,937

25,333

19,085

17,562

Other operating income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,250

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Operating loss

-15,886

-10,715

-18,116

-19,093

-18,235

-14,552

-25,048

-14,338

-12,418

-13,282

-14,305

-15,560

-15,253

-11,677

36,203

-5,711

-5,711

-7,306

-10,024

-11,708

-10,266

-12,954

36,736

-11,087

-9,325

-8,923

-10,512

-12,273

-11,272

-341

-11,315

-10,734

-13,101

-10,762

-11,447

55,470

-22,945

-17,118

-15,257

Other (expense) income:
Interest (expense) income and other income, net

-915

-543

-726

-607

-500

-235

-762

-930

-1,006

-1,055

-1,047

-1,076

-1,107

-703

79

43

54

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

54

-

-

10

11

12

-

12

13

12

10

12

10

14

17

14

14

15

16

15

16

18

17

16

Total other (expense) income

-915

-543

-726

-607

-500

-235

-762

-930

-1,006

-1,055

-1,047

-1,076

-1,107

-714

79

54

54

19

10

11

12

14

12

13

12

10

12

10

14

17

14

14

15

16

15

16

18

17

16

Loss before income tax (expense) benefit

-

-

-18,842

-19,700

-

-

-25,810

-15,268

-

-

-15,352

-16,636

-

-

-

-

-

-

-

-

-

-

36,748

-11,074

-

-

-10,500

-12,263

-

-

-

-

-

-

-

-

-

-

-

Income tax (expense) benefit

-

-

-

-

-

-

-1,453

-96

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-227

-1

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

Net (loss) income

-

-

-

-

-

-

-

-

-

-

-

-

-

-14,235

36,282

-5,657

-5,657

-7,154

-10,014

-11,697

-10,254

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss attributable to noncontrolling interests

-

-

-

-

-

-

-

-

-

-

-

-

-

-14

-21

-19

-19

-7

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-16,801

-11,275

-18,842

-19,700

-18,735

-14,704

-24,357

-15,172

-13,424

-2,665

-15,352

-16,636

-16,360

-14,221

36,303

-5,638

-5,638

-7,147

-10,014

-11,697

-10,254

-12,179

36,975

-11,073

-9,313

-8,551

-10,500

-12,263

-11,258

-324

-11,301

-10,720

-13,086

-10,746

-11,432

55,486

-22,927

-17,101

-15,241

Net (loss) income per share attributable to Progenics - basic (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.52

-

-

-

-0.14

-

-

-0.16

0.53

-0.16

-0.15

-0.13

-0.17

-0.24

-0.22

0.02

-0.33

-0.32

-0.39

-

-0.34

1.66

-

-0.52

-0.47

Weighted-average shares - basic (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

69,705

-

-

69,665

69,556

69,561

63,958

60,996

60,599

51,481

50,116

37,609

33,848

33,798

33,761

-

33,710

33,510

-

-

-

Net (loss) income per share attributable to Progenics - diluted (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.52

-

-

-

-0.14

-

-

-

0.51

-

-

-

-0.17

-

-

-

-

-

-

-

-0.34

1.64

-

-

-

Weighted-average shares - diluted (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

70,297

-

-

-

69,705

-

-

-

72,879

-

-

-

60,599

-

-

-

-

-

-

-

33,710

33,787

-

32,814

32,396

Net loss per share - basic and diluted (in dollars per share)

-0.19

-0.13

-0.22

-0.23

-0.22

-0.18

-0.30

-0.20

-0.19

-0.04

-0.22

-0.24

-0.23

-

-

-0.08

-0.08

-

-

-0.17

-0.15

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.69

-0.52

-0.47

Weighted-average shares - basic and diluted (in shares)

86,582

86,465

86,421

85,000

84,542

84,701

80,325

74,017

72,517

70,468

70,270

70,202

70,196

-

70,013

69,947

69,947

-

-

69,647

69,637

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

33,273

32,814

32,396

Product [Member]
Revenue

1,359

-

570

270

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Royalty [Member]
Revenue

4,789

4,304

4,912

3,593

4,161

3,151

5,169

3,530

3,058

-

2,562

-

-

2,216

3,319

2,380

2,380

3,453

1,208

1,773

174

-627

1,626

1,367

735

2,871

719

1,176

1,157

782

728

1,619

1,834

1,279

1,240

527

0

620

581

License and Other [Member]
Revenue

100

10,103

131

6,103

120

-

148

348

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Product and Service, Other [Member]
Revenue

-

-

-

-

-

-

-

-

131

-

135

-

-

-3,535

50,523

6,073

6,073

1,562

183

145

65

52

40,023

72

1,049

83

145

514

853

8,004

136

94

291

366

2,855

72,460

1,083

82

880